| 1/27/2021 |
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform |
vcaonline.com |
... inflammation-mediated autoimmune diseases and is initially focused on a potentially efficacious, yet less immunosuppressive option for the treatment of RA. This financing was led by New Enterprise Associates (NEA) and included returning investors Action Potential Venture Capital , Boston Scientific, Topspin Fund, Morgenthaler, Euclidean Capital and an undisclosed strategic investor. New investors including ShangBay Capital, Richard King Mellon Foundation, Ascendum Capital, Asahi Kasei, Catalio Capital Management, BPC Fund, Midas Capital ... |
| 8/31/2020 |
GSK-backed venture fund APVC sees opportunities in ultrasound | |
medicaldesignandoutsourcing.com |
Juan-Pablos Mas of APVC details the firms investment in EXO. Action Potential Venture Capital , a corporate investment arm of GSK, sees therapeutic opportunities in ultrasound, according to a partner at the group. In this week’s DeviceTalks Weekly Podcast, Action Venture partner Juan-Pablo Mas explains why APCV led the recent round in Exo , a maker of the first piezoelectric micromachined ultrasonic transducer (PMUT) portable ultrasound imaging technology. Mas also ... |
| 8/25/2020 |
Handheld Medical Imaging Company Exo Raises $40 Million |
pulse2.com |
... a $40 million Series B+ funding round that will fund research and product development on a handheld medical device and cloud-based workflow software platform. Fiscus Ventures and Reimagined Ventures (Magnetar Capital affiliates) and Action Potential Venture Capital led the investment with additional participation from TDK Ventures, Solasta Ventures and all previous investors, including Intel Capital, Applied Ventures, Bold Capital, Creative Ventures, Longevity Vision Fund, Fiscus and Reimagined Ventures, Nautilus ... |
| 8/24/2020 |
TDK Ventures backs handheld ultrasound imaging startup, Exo |
electronicsmaker.com |
A pioneering health information and devices company, Exo (pronounced “Echo”) is TDK Ventures’ first in the point-of-care diagnostics space. Additional investors include Action Potential Venture Capital , a Corporate VC arm of GlaxoSmithKline and Magnetar Capital, an affiliate of Fiscus Ventures and RIVC Ventures. Redwood City, California-based Exo develops miniaturized ultrasound devices for applications in emergency medicine, critical care, vascular, anesthesiology, tomography, precision endoscopy, non-invasive neuromodulation, and ... |
| 8/24/2020 |
TDK Ventures backs handheld ultrasound imaging startup, Exo |
pressreleasepoint.com |
A pioneering health information and devices company, Exo (pronounced “Echo”) is TDK Ventures’ first in the point-of-care diagnostics space. Additional investors include Action Potential Venture Capital , a Corporate VC arm of GlaxoSmithKline and Magnetar Capital, an affiliate of Fiscus Ventures and RIVC Ventures. Redwood City, California-based Exo develops miniaturized ultrasound devices for applications in emergency medicine, critical care, vascular, anesthesiology, tomography, precision endoscopy, non-invasive neuromodulation, and ... |
| 8/21/2020 |
Exo raises $40M for handheld ultrasound; decentralized trial platforms raise nearly $100M; and more digital health funding news |
MobiHealthNews |
... 5 million seed funding and announces exclusive commercialization deal. 02:24 pm Share Exo, a Silicon Valley company known for its in-development handheld ultrasound device, announced $40 million in new funding yesterday. GlaxoSmithKline's Investor Action Potential Venture Capital fund was among the Series B+ round's unnamed investors. Exo said in its announcement that it will be using the funds to wrap up product development for that device, and to bring ... |
| 8/20/2020 |
Exo raises $40 million to bring high-quality ultrasound to handheld devices |
VentureBeat |
... last August with around $48 million in funding spread across several funding rounds, with notable backers including Intel Capital, which returned for this series B+ round alongside lead investors Fiscus Ventures, Reimagined Ventures, and Action Potential Venture Capital . With another $40 million in the bank, the company said it’s now well-positioned to bring its data and workflow apps to market and to conclude product development for its handheld ultrasound ... |
| 7/16/2020 |
Presidio Medical raises $30m for pain relief neuromod tech - MassDevice |
Mass Device |
... the investment will be used to develop the technology further to treat chronic pain and expand applications of the platform to address other unmet indications. The financing round was led by Invus Opportunities and Action Potential Venture Capital . Filed Under: Neuromodulation/Neurostimulation Tagged With: Presidio Medical In case you missed it Tegra Medical announces major expansions in Massachusetts and Mississippi Tegra Medical announced today that it has purchased an additional ... |
| 7/15/2020 |
Presidio Medical raises $30m to develop neuromodulation platform |
medicaldevice-network.com |
US-based medical device company Presidio Medical has raised $30m in a funding round led by Invus Opportunities. The round was also joined by the company’s existing investor Action Potential Venture Capital . Presidio Medical plans to use the funds for the development of its neuromodulation technology platform to treat chronic pain. South San Francisco-based company also plans to expand the platform application to include additional indications. Presidio Medical’s neuromodulation ... |
| 7/14/2020 |
Presidio Medical Announces $30 Million Financing Round Led by Invus Opportunities |
BioSpace |
... a neuromodulation platform technology with an initial indication to treat chronic pain, today announced it has closed $30 million in financing. The financing round was led by Invus Opportunities, with participation from existing investor, Action Potential Venture Capital . Presidio Medical’s technology is designed to provide pain relief across a broad spectrum of pain types where conventional treatment has failed. Patients who fail or receive minimal relief from standard pain treatment ... |
| 7/8/2020 |
CVRx raises fresh funds to support commercialisation of BAROSTIM NEO |
medicaldevice-network.com |
... S.H.I.P.) and Vensana Capital. It was also joined by new investors such as Hatteras Venture Partners and Venrock Healthcare Capital Partners. The company’s existing investors Johnson & Johnson Innovation, New Enterprise Associates, Gilde Healthcare and Action Potential Venture Capital also took part in the financing round. As part of the financing, S.H.I.P. general partner Mudit Jain and Vensana Capital general partner Kirk Nielsen will join the CVRx board of directors. CVRx ... |
| 7/7/2020 |
CVRx® Raises $50 Million in New Equity Financing |
PR Newswire |
... investors Strategic Healthcare Investment Partners ("S.H.I.P.") and Vensana Capital, with participation from other new investors, Hatteras Venture Partners and Venrock Healthcare Capital Partners. Existing investors Johnson & Johnson Innovation, New Enterprise Associates, Gilde Healthcare, and Action Potential Venture Capital also participated in this financing round. "It is a great vote of confidence in our product and mission that we were able to close this oversubscribed financing round amid such volatile market ... |
| 5/24/2019 |
Cala Health nets $50M to market its tremor-treating wearable |
FierceBiotech |
... expand its therapeutic pipeline. The series C round saw new investments from Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and others. Cala’s previous backers also returned, including Johnson & Johnson Innovation, Lux Capital, Lightstone Ventures, Action Potential Venture Capital , GV and dRx Capital, a joint investment company between Novartis and Qualcomm. “This financing follows exciting momentum from the past year, including receiving de novo clearance from the Food and Drug Administration ... |
| 5/23/2019 |
Bioelectronic Medicine Startup Cala Health Nabs $50M for Wearable Neuromodulation Therapies |
HIT Consultant |
... in the Series C funding round include Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others. All existing investors participated in the round, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Lux Capital, Lightstone Ventures, Action Potential Venture Capital , dRx Capital, and GV. Founded in 2014, Carla Health is transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized ... |
| 5/21/2019 |
Cala Health's $50M Series C will bring its wearable essential tremor therapy to market - plugilo.blog |
MobiHealthNews |
... focused on chronic diseases, has closed a $50 million Series C financing round. Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and other unnamed backers participated, as did returning investors JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital , dRx Capital and GV. WHAT THEY DO Stanford University spinout Cala Health has created a wearable neuromodulation therapy indicated for essential tremor, with other offerings under development focused on neurology, cardiology and ... |
| 12/6/2017 |
Bioelectronic medicine — for back pain, brain cancer, and more — may be the fastest-growing alternative to drugs |
Boston Globe |
... effects of a drug-based treatment. These advantages have the health care industry excited about electricity. “The body is filled with nerves and those nerves are conducting electricity,” says Imran Eba, a partner at Action Potential Venture Capital in Cambridge, a fund started by pharma giant GlaxoSmithKline (GSK) that so far has invested more than $100 million in seven bioelectronic medicine startups. “If we can understand how those electrical signals ... |